PCI术后应重视CIN

2012-06-17 范振光 临床心血管病杂志

       天津医科大学研究生院和天津市胸科医院心内科周小雨、李英、李珊珊等在《临床心血管病杂志》2012年第5期发表一项研究探讨了冠状动脉介入治疗(PCI)术后对比剂肾损伤(CIN)发病情况及危险因素。分析表明,CIN是PCI术后较常见的并发症,对具备CIN高危因素的患者,临床医生应高度重视。        

       天津医科大学研究生院和天津市胸科医院心内科周小雨、李英、李珊珊等在《临床心血管病杂志》2012年第5期发表一项研究探讨了冠状动脉介入治疗(PCI)术后对比剂肾损伤(CIN)发病情况及危险因素。分析表明,CIN是PCI术后较常见的并发症,对具备CIN高危因素的患者,临床医生应高度重视。
 
       研究者回顾性调查了天津市胸科医院心内科2009-01-2010-12行PCI术的1435例患者,根据是否发生CIN将其分为CIN组和非CIN组,比较2组之间相关因素的差异,应用Logistic回归分析确定CIN的危险因素。
 
       结果显示,1435例患者中有211例发生CIN,发病率为14.7%;CIN组和非CIN组间年龄、红细胞计数、血红蛋白含量、贫血、血压、左室射血分数(LVEF)、肾小球滤过率(GFR)、对比剂用量等均差异有统计学意义(均P<0.05)。多因素Logistic回归分析显示,年龄>70岁、糖尿病、低血压、贫血、LVEF≤45%、GFR≤60ml/(min.1.73m2)、对比剂用量>200ml、心肌梗死、急诊PCI是CIN的危险因素。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1773429, encodeId=d6f41e7342930, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Oct 09 08:17:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633792, encodeId=9ef51633e92f9, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Fri Nov 02 02:17:00 CST 2012, time=2012-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486398, encodeId=2260148639898, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Tue Jun 19 11:17:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
    2012-10-09 kalseyzl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1773429, encodeId=d6f41e7342930, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Oct 09 08:17:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633792, encodeId=9ef51633e92f9, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Fri Nov 02 02:17:00 CST 2012, time=2012-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486398, encodeId=2260148639898, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Tue Jun 19 11:17:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
    2012-11-02 zxl736
  3. [GetPortalCommentsPageByObjectIdResponse(id=1773429, encodeId=d6f41e7342930, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Oct 09 08:17:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633792, encodeId=9ef51633e92f9, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Fri Nov 02 02:17:00 CST 2012, time=2012-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486398, encodeId=2260148639898, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Tue Jun 19 11:17:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]